PLG plasminogen
ENSG00000122194 · protein coding · Open Targets profile
[Plasmin]: Protease which primary function is to degrade fibrin, the main component of blood clots (PubMed:6094526, PubMed:6919539). Also cleaves other components of blood clots like thrombospondin-1/THBS1 and von Willebrand factor (VWF) (PubMed:24449821, PubMed:7679575). Can also directly and/or through the activation of other proteases degrade the various components of the extracellular matrix including collagen, fibronectin and laminin (PubMed:14699093, PubMed:28849762, PubMed:9171346). Thereby, regulates a variety of biological processes including embryonic development, tissue remodeling, and inflammation (PubMed:9171346). In ovulation, weakens the walls of the Graafian follicle (By similarity). In vitro, it is also able to cleave several complement zymogens, such as C1, C4 and C5 (PubMed:6447255). {ECO:0000250|UniProtKB:Q01177, ECO:0000269|PubMed:14699093, ECO:0000269|PubMed:24449821, ECO:0000269|PubMed:28849762, ECO:0000269|PubMed:6094526, ECO:0000269|PubMed:6447255, ECO:0000269|PubMed:6919539, ECO:0000269|PubMed:7679575, ECO:0000269|PubMed:9171346}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Approved Drug, Structure with Ligand, High-Quality Ligand, Med-Quality Pocket, Druggable Family
- Antibody
- UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM
- PROTAC
- Half-life Data, Small Molecule Binder
- Other modalities
- Approved Drug
gnomAD loss of function constraint: o/e 0.39267998933792114 (upper bound 0.5095099806785583). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 318 registry trials, updated in the last three years, of the most advanced drugs against PLG (defibrotide, streptokinase, anistreplase, aminocaproic acid, tranexamic acid, amediplase, desmoteplase), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Ian RobertsLondon School of Hygiene and Tropical Medicine (Clinical Trials Unit) · 3 of 3 trials Phase 2+
- Andre LamyPopulation Health Research Institute · 2 of 2 trials Phase 2+
- Arthur HertlingNYU Langone Health · 2 of 2 trials Phase 2+
- David ChiuNYU Langone Health · 2 of 2 trials Phase 2+
- Haleema Shakur-StillLondon School of Hygiene and Tropical Medicine · 2 of 2 trials Phase 2+
- Małgorzata DomagalskaPoznań University of Medical Sciences · 2 of 2 trials Phase 2+
- Mauricio E Perez PachonDepartment of Plastic Surgery | Scientific Division | Total Definer · 2 of 2 trials Phase 2+
- Mitchell CairoNew York Medical College · 2 of 2 trials Phase 2+
- Paul S MylesAlfred Hospital and Monash University · 2 of 2 trials Phase 2+
- Ali AmarCombined Military Hospital Abbottabad · 1 of 2 trials Phase 2+
- Tae-Yop KimKonkuk University Medical Center · 1 of 2 trials Phase 2+
- Ahmed M ELGHONEIMY57357 children cancer hospital · 1 of 1 trials Phase 2+
- Ahmed N AfifiKafrelsheikh University · 1 of 1 trials Phase 2+
- Ahmed N ShakerKafrelsheikh University · 1 of 1 trials Phase 2+
- Aiman SattarJinnah Hospital/AIMC/UHS · 1 of 1 trials Phase 2+
Registry trials of defibrotide, streptokinase, anistreplase, aminocaproic acid, tranexamic acid, amediplase, desmoteplase updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 278 of 287 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 31 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
86 trials of drugs against PLG were stopped early; 5 give no reason
Terminated, withdrawn and suspended interventional trials of defibrotide, streptokinase, anistreplase, aminocaproic acid, tranexamic acid, amediplase, desmoteplase, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 86.
- terminated · 2026-10-26 · Population Health Research Institute · Tranexamic Acid“Upon the Data Safety Monitoring Board review of the interim analysis (75% of participants have finished their follow-up) on November 17, 2023, they made a recommendation to stop recruitment into the trial.”
- withdrawn · 2026-07-23 · University of Minnesota · 1%Tranexamic acid with standard local“Lack of Participants”
- terminated · 2026-06-24 · SHI Jia · matched by the registry's drug synonyms“At a meeting on February 17, 2025, the Data and Safety Monitoring Board recommended early termination because the predefined efficacy boundary was crossed.”
- withdrawn · 2026-03-03 · Campbell Clinic · Tranexamic Acid (TXA)“Difficulty with study implement study related to staffing issue \& approvals.”
- terminated · 2025-09-29 · University of California, San Francisco · Tranexamic Acid“Slow Accrual”
- terminated · 2025-07-22 · Istituto Ortopedico Rizzoli · Tibial osteotomy with Tranexamic acid“Patient enrollment was proceeding slower than planned”
- terminated · 2025-05-21 · University of Kansas Medical Center · Tranexamic Acid (TXA)“recruitment stalled”
- terminated · 2025-05-20 · North York General Hospital · matched by the registry's drug synonyms“The study was prematurely terminated due to a long pause in study activities and significant missing participant data.”
- withdrawn · 2025-05-02 · University of Florida · Tranexamic acid“Study not moving forward due to upcoming PI departure”
- withdrawn · 2025-04-14 · University Hospital, Basel, Switzerland · tranexamic acid, ferric carboxymaltose and tranexamic acid“Issue with grant transfer upon sponsor relocation”
- withdrawn · 2025-02-21 · Northwestern University · Tranexamic acid“Medical student graduated and stopped project”
- withdrawn · 2025-01-31 · The University of Texas Medical Branch, Galveston · Tranexamic acid“closed study due to lack of faculty”
- terminated · 2024-12-20 · St. Jude Children's Research Hospital · Tranexamic Acid“Per sponsor”
- withdrawn · 2024-12-13 · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Tranexamic acid (TXA)“Lack of staffing”
- terminated · 2024-11-19 · Riley McLean · Tranexamic acid injection“Drug supply issues”
- terminated · 2024-10-21 · University of Nove de Julho · matched by the registry's drug synonyms“Due to implementation challenges, we categorized this study as a pilot and ended data collection, intending to adapt methods for future trials. Although the initial sample size was 54, data from 21 participants were analyzed.”
- withdrawn · 2024-10-15 · University of Kansas Medical Center · Tranexamic Acid“Administrative withdrawal-study not approved by IRB”
- withdrawn · 2024-08-07 · University of California, San Francisco · Defibrotide“Industry sponsor decision”
- terminated · 2024-08-01 · Universitaire Ziekenhuizen KU Leuven · Tranexamic Acid“Advice from DSMB”
- withdrawn · 2024-07-23 · Northwestern University · Tranexamic acid injection“Stopped study due to pharmacy issues before treating patients”
- terminated · 2024-07-01 · Margaret Ragni · tranexamic acid“The study stopped early due to slow recruitment.”
- terminated · 2024-06-26 · NYU Langone Health · Tranexamic acid, Aminocaproic acid“Both lack of enrollment as well as study staff turnover”
- terminated · 2024-03-26 · NYU Langone Health · Tranexamic Acid Injection (TXA)“Enrollment rate was slower than anticipated”
- terminated · 2024-03-12 · NYU Langone Health · Tranexamic acid (TXA) injection“Enrollment rate was slower than anticipated.”
- withdrawn · 2024-02-08 · Azienda U.S.L. 1 di Massa e Carrara · Tranexamic Acid“Authorization denied”
Paediatric incentives and obligations for PLG's drugs
For defibrotide, streptokinase, anistreplase, aminocaproic acid, tranexamic acid, amediplase, desmoteplase: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · PLG is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: no · No EMA paediatric investigation plan decision names defibrotide, streptokinase, anistreplase, aminocaproic acid, tranexamic acid, amediplase, desmoteplaseRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: yes · EU/3/04/211 withdrawn 29 Jul 2004: Prevention of hepatic veno-occlusive disease; EU/3/13/1201 withdrawn 13 Nov 2013: Prevention of graft-versus-host disease; EU/3/04/212 positive 29 Jul 2004: Treatment of hepatic veno-occlusive diseaseRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Defitelio: authorised since 18 Oct 2013, exceptional circumstancesRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA EPAR Defitelio, 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of defibrotide, streptokinase, anistreplase, aminocaproic acid, tranexamic acid, amediplase, desmoteplaseRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 132 interventional studies of defibrotide, streptokinase, anistreplase, aminocaproic acid, tranexamic acid, amediplase, desmoteplase include patients under 18; 17 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 9 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.